Allergen-specific immunotherapy can prevent disease progression in the long term by tolerance development in allergic diseases. However, to achieve sustainable effects, long-term therapy is required, which requires a certain degree of adherence on the part of the patient. However, data show that treatment dropout rates are sometimes substantial. Which factors could be decisive for this, or how adherence can be promoted, is a much-discussed practice-relevant topic, on which there are numerous smaller and larger studies.
This content is machine-translated. Please contact us if you need professional translation services.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Chronic urticaria
“Treat-to-target” approach is underpinned by new findings
- Dual GIP/GLP-1 RA in type 2 diabetes
Tirzepatide proves multiple benefits
- Pain syndrome
From pathophysiology to therapy – a reminder
- Sunscreen
Increasing risk of skin cancer due to dangerous UV radiation
- Coronary heart disease and type 2 diabetes
Relationship between baseline FFA values and all-cause mortality.
- Esophagus
Therapy of esophageal carcinoma – an overview
- Visceral Surgery Update - Part 1
Upper gastrointestinal tract and robotic visceral surgery
- Case reports: Pityriasis rubra pilaris (PRP)